Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial
Novartis Pharmaceuticals
David R Matthews; Päivi M Paldánius; Pieter Proot; YannTong Chiang; Michael Stumvoll; Stefano Del Prato